All In Biotech

Drug Trial Radar · NCT07944885

First-in-human Study of SAR448632 in Healthy Adult Participants

A Randomized, First-in-human, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of SAR448632 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Aug 15, 2027

Study completion Aug 15, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, first-in-human, placebo-controlled, double-blind, Phase 1 study to assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and target engagement after sequential single ascending doses of SAR448632 in healthy adult male and female participants.

Conditions

  • Healthy Volunteer

Interventions

  • PlaceboDrug

    Administration method will match SAR448632

  • SAR448632Drug

    Route of administration: SC injection or infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with assessment of Adverse Events (AEs) / Treatment-Emergent Adverse Events (TEAEs), including Injection Site Reactions (ISRs)Time frame: Baseline to day 113
  2. Number of participants with potentially clinically significant abnormalities in clinical laboratory evaluation; Vital signs; 12-lead Electrocardiogram.Time frame: Baseline to day 113

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.